In recent years, immune checkpoint inhibitors (ICIs), particularly antibodies targeting the PD-1/PD-L1 and CTLA-4 pathways, have revolutionized cancer therapy and significantly improved outcomes in subsets of patients (3, 4). Here, CD274 is linked to cancer.